POOJA BHADORIYA¹, RICHA SHARMA¹, REKHA MEHROTRA¹, SIMRAN KAUR¹, ISHA SRIVASTAVA¹, MUKUL JAIN², PRASHANT KAUSHIK^3,*

BIOCELL, Vol.47, No.9, pp. 1915-1930, 2023, DOI:10.32604/biocell.2023.029564

Abstract In the present medicine world antibiotic resistance is one of the key threats to universal health coverage. Researchers continue to work hard to combat this global health concern. Phage therapy, an age-old practice during the early twentieth century, was outshined by the discovery of antibiotics. With the advent of widespread antibiotic resistance, phage therapy has again redeemed itself as a potential alternative owing to its adeptness to target bacteria precisely. Limited side effects, the ability to migrate to different body organs, a distinct mode of action, and proliferation at the infection site, make phages a profitable candidate to replace conventional… More > Graphic Abstract

SUNG HEE LIM^1,#, HEE JIN CHO^1,2,3,#, KYOUNG-MEE KIM⁴, HO YEONG LIM¹, WON KI KANG¹, JEEYUN LEE¹, YOUNG SUK PARK¹, HEE CHEOL KIM^5,*, SEUNG TAE KIM^1,*

Oncology Research, Vol.31, No.6, pp. 855-866, 2023, DOI:10.32604/or.2023.030374

Abstract Background: Although bevacizumab is an important treatment for metastatic colorectal cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations, only modest survival benefits have been reported. Methods: We evaluated clinical outcomes in 110 patients using comprehensive molecular characterization to identify biomarkers for a response to bevacizumab-containing treatment. The molecular analysis comprised whole-exome sequencing, ribonucleic acid sequencing, and a methylation array on patient tissues. Results: Genomic and molecular characterization was successfully conducted in 103 patients. Six of 103 CRC samples were hypermutated, and none of the non-hypermutant tumors were microsatellite unstable. Among those 103 patients, 89… More >

RUI ZHANG^1,2,#, PENG ZHOU^1,3,#, XIA OU⁴, PEIZHU ZHAO², XIJING GUO², MIAN XI^5,*, CHEN QING^1,*

Oncology Research, Vol.31, No.6, pp. 887-897, 2023, DOI:10.32604/or.2023.030184

Abstract Esophageal squamous cell carcinoma (ESCC) is among the most prevalent causes of cancer-related death in patients worldwide. Resistance to immunotherapy and chemotherapy results in worse survival outcomes in ESCC. It is urgent to explore the underlying molecular mechanism of immune evasion and chemoresistance in ESCC. Here, we conducted RNA-sequencing analysis in ten ESCC tissues from cisplatin-based neoadjuvant chemotherapy patients. We found that DMRTA1 was extremely upregulated in the non-pathologic complete response (non-pCR) group. The proliferation rate of esophageal squamous carcinoma cells was markedly decreased after knockdown of DMRTA1 expression, which could increase cisplatin sensitivity in ESCC. Additionally, suppression of DMRTA1… More >

MUNEEBA MALIK¹, MAMOONA MAQBOOL², TOOBA NISAR³, TAZEEM AKHTER⁴, JAVED AHMED UJAN^5,6, ALANOOD S. ALGARNI⁷, FAKHRIA A. AL JOUFI⁸, SULTAN SHAFI K. ALANAZI⁹, MOHAMMAD HADI ALMOTARED¹⁰, MOUNIR M. SALEM BEKHIT¹¹, MUHAMMAD JAMIL^12,*

Oncology Research, Vol.31, No.6, pp. 899-916, 2023, DOI:10.32604/or.2023.030760

Abstract The low survival rate of Kidney renal clear cell carcinoma (KIRC) patients is largely attributed to cisplatin resistance. Rather than focusing solely on individual proteins, exploring protein-protein interactions could offer greater insight into drug resistance. To this end, a series of in silico and in vitro experiments were conducted to identify hub genes in the intricate network of cisplatin resistance-related genes in KIRC chemotherapy. The genes involved in cisplatin resistance across KIRC were retrieved from the National Center for Biotechnology Information (NCBI) database using search terms as “Kidney renal clear cell carcinoma” and “Cisplatin resistance”. The genes retrieved were analyzed… More >

TONG WANG^1,4,#, JINHUAN HONG^1,5,#, JIAJIE XIE^1,5, QIAN LIU⁴, JINRUI YUE^1,5, XUTING HE^1,5, SHIYU GE⁴, TAO LI⁴, GUOXIN LIU⁴, BENZHI CAI^1,3,5, LINQIANG LI^2,*, YE YUAN^1,3,5,*

BIOCELL, Vol.47, No.8, pp. 1811-1820, 2023, DOI:10.32604/biocell.2023.029120

Abstract Background: Phototherapies based on sunlight, infrared, ultraviolet, visible, and laser-based treatments present advantages like high curative effects, small invasion, and negligible adverse reactions in cancer treatment. We aimed to explore the potential therapeutic effects of blue light emitting diode (LED) in human hepatoma cells and decipher the underlying cellular and molecular mechanisms. Methods: Wound healing and transwell assays were employed to probe the inhibition of the invasion and migration of hepatocellular carcinoma cells in the presence of blue LED. The sphere-forming test was used to evaluate the effect of LED blue light irradiation on cancer stem cell properties. Immunofluorescence and… More > Graphic Abstract

CARL RANDALL HARREL¹, VALENTIN DJONOV², ANA VOLAREVIC³, DRAGICA PAVLOVIC⁴, VLADISLAV VOLAREVIC^4,5,*

BIOCELL, Vol.47, No.8, pp. 1757-1769, 2023, DOI:10.32604/biocell.2023.028567

Abstract Exosomes derived from mesenchymal stem cells (MSC-Exos) are nano-sized extracellular vesicles enriched with bioactive molecules, such as microRNAs, enzymes, cytokines, chemokines, immunomodulatory, trophic, and growth factors. These molecules regulate the survival, phenotype, and function of malignant and tumor-infiltrated immune cells. Due to their nano-size and bilayer lipid envelope, MSC-Exos can easily bypass biological barriers and may serve as drug carriers to deliver chemotherapeutics directly into the tumor cells. Here, we summarize current knowledge regarding molecular mechanisms responsible for MSC-Exos-dependent modulation of tumor progression and discuss insights regarding the therapeutic potential of MSC-Exos in the treatment of malignant diseases. More > Graphic Abstract

YIFAN LI^1,2, JING ZHANG¹, YITAO FAN¹, HANDAN XIAO¹, KEXIN KANG¹, YALI ZHOU¹, ZHIWEN ZHANG^3,*, YUMIN LI¹, MUZHOU TENG^1,*

BIOCELL, Vol.47, No.8, pp. 1783-1791, 2023, DOI:10.32604/biocell.2023.028056

Abstract Background: ((1-triphenylaminebenzo[c][1,2,5] thiadiazole-4-yl) styryl)-1-methylpyridin methylpyridin-1-ium iodide salt (TBZPy) is a novel photosensitizer that displays excellent photodynamic properties. However, There are few reports on the mechanism of action of the TBZPy photodynamic. Previous studies revealed that photodynamic therapy (PDT) could induce endoplasmic reticulum stress by acting on the endoplasmic reticulum. Therefore, in this study, we investigated the effects of endoplasmic reticulum stress induced by TBZPy-PDT in treating High-risk human papillomavirus (HR-HPV) infection and their underlying mechanisms. Methods: The human cervical cancer cell line HeLa (containing whole genome of HR-HPV18) was treated with TBZPy-PDT. Cell migration, invasion, and colony-forming ability were evaluated… More > Graphic Abstract

SUKRAN SENYUREK¹, SEZER SAGLAM^2,*, ESRA KAYTAN SAGLAM³, HAKAN YANAR⁴, KAAN GOK⁴, DIDEM TASTEKIN⁵, CANAN KOKSAL AKBAS⁶, NERGIZ DAGOGLU SAKIN³, GULBIZ DAGOGLU KARTAL⁷, EMRE BALIK⁸, METIN KESKIN⁴, YASEMIN SANLI⁹, MINE GULLUOGLU¹⁰, ZULEYHA AKGUN¹¹

Oncology Research, Vol.31, No.5, pp. 689-696, 2023, DOI:10.32604/or.2023.030351

Abstract Radiation therapy (RT) is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer (LARC): short-course RT (SC-RT) alone or long-course RT (LC-RT) with concurrent fluorouracil (5-FU) chemotherapy. The Phase II single-arm KROG 11-02 study using intermediate-course (IC) (33 Gy (Gray)/10 fr (fraction) with concurrent capecitabine) preoperative chemoradiotherapy (CRT) demonstrated a pathologically complete response rate and a sphincter-sparing rate that were close to those of LC-CRT. The current trial aim to compare the pathological/oncological outcomes, toxicity, and quality of life results of LC-CRT and IC-CRT in cases of LARC. The prescribed dose was… More >

MUHAMMAD BABAR KHAWAR^1,2,3,#, YAJUN WANG^4,#, ANEEQA MAJEED³, ALI AFZAL⁵, KABEER HANEEF⁶, HAIBO SUN^1,2,*

Oncology Research, Vol.31, No.5, pp. 677-688, 2023, DOI:10.32604/or.2023.029718

Abstract Hepatocellular carcinoma, the most common primary liver cancer and a leading cause of death, is a difficult disease to treat due to its heterogeneous nature. Traditional models, such as 2D culture and patient-derived xenografts, have not proven effective. However, the development of 3D culture techniques, such as organoids, which can mimic the tumor microenvironment (TME) and preserve heterogeneity and pathophysiological properties of tumor cells, offers new opportunities for treatment and research. Organoids also have the potential for biomarker detection and personalized medication, as well as genome editing using CRISPR/Cas9 to study the behavior of certain genes and therapeutic interventions. This… More > Graphic Abstract

XUEFENG WANG^1,#, SICONG JIANG^2,#, XINHONG ZHOU³, XIAOFENG WANG⁴, LAN LI⁵, JIANJUN TANG^1,*

Oncology Research, Vol.31, No.5, pp. 697-714, 2023, DOI:10.32604/or.2023.029458

Abstract Background: Pancreatic cancer is associated with high mortality and is one of the most aggressive of malignancies, but studies have not fully evaluated its molecular subtypes, prognosis and response to immunotherapy of different subtypes. The purpose of this study was to explore the molecular subtypes and the key genes associated with the prognosis of pancreas cancer patients and study the clinical phenotype, prognosis and response to immunotherapy using single-cell seq data and bulk RNA seq data, and data retrieved from GEO and TCGA databases. Methods: Single-cell seq data and bioinformatics methods were used in this study. Pancreatic cancer data were… More >